Advances in the medical management of benign prostatic hyperplasia.
作者信息
Jewett Michael A S, Klotz Laurence H
机构信息
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ont.
出版信息
CMAJ. 2007 Jun 19;176(13):1850-1. doi: 10.1503/cmaj.060439.
Abstract
摘要
相似文献
1
Advances in the medical management of benign prostatic hyperplasia.
CMAJ. 2007 Jun 19;176(13):1850-1. doi: 10.1503/cmaj.060439.
2
Finasteride in benign prostatic hyperplasia.
N Engl J Med. 2004 Mar 25;350(13):1359-61; author reply 1359-61.
3
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Aktuelle Urol. 2004 Sep;35(5):339-42. doi: 10.1055/s-2004-834352.
4
Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
Can J Urol. 2005 Feb;12(1):2508-9; author reply 2509-10.
5
Benign prostatic hyperplasia (BPH).
Harv Mens Health Watch. 2006 Aug;11(1):3.
6
[5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
MMW Fortschr Med. 2002 Oct 31;144(44):56.
7
Benign prostatic hyperplasia.
Hosp Med. 2003 Feb;64(2):114.
8
Second opinion. I have benign prostatic hyperplasia. The drug my doctor prescribed has helped somewhat, but I'm still making a lot of trips to the bathroom at night. Short of surgery, are there any new approaches to managing this condition that might be more helpful?
Mayo Clin Health Lett. 2002 Dec;20(12):8.
9
The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
Adv Ther. 1995 Nov-Dec;12(6):361-6.
10
[Benign prostatic hyperplasia: medical therapy].
MMW Fortschr Med. 2007 Aug 16;149(33-34):29-31; quiz 32.
引用本文的文献
1
Finasteride therapy for benign prostatic hyperplasia.
CMAJ. 2008 Feb 26;178(5):596-7. doi: 10.1503/cmaj.1070095.
本文引用的文献
1
The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
J Urol. 2004 Oct;172(4 Pt 1):1297-301. doi: 10.1097/01.ju.0000139993.51181.5d.
2
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918.
3
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656.
4
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Urology. 1999 Oct;54(4):662-9. doi: 10.1016/s0090-4295(99)00232-0.
5
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
N Engl J Med. 1998 Feb 26;338(9):557-63. doi: 10.1056/NEJM199802263380901.
6
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
N Engl J Med. 1991 Apr 25;324(17):1156-61. doi: 10.1056/NEJM199104253241702.
Zotero 插件